Skip to main content

Table 1 Summary of clinical events and treatment over time

From: Modified protocol of omalizumab treatment to prevent carboplatin-induced drug hypersensitivity reactions: a case study

YearEventSurgical debulkingAdjuvant chemotherapyAllergology
2008Stage III ovarian cancer of the endometrioid typeYes6 Cycles of carboplatin and paclitaxel 
2009
2010Disease relapseYesNo 
2011
2012
2013Disease relapseYesNo 
2014Symptomatic platinum-sensitive disease relapseNot possible2 Cycles of carboplatin/paclitaxel
Cycle 3 omitted
Cycle 4–6 according to 10-step desensitisation schedule
Cycle 2: allergic reaction
Skin tests positive for carboplatin, negative for paclitaxel
2015
2016
2017Symptomatic platinum-sensitive disease relapseNo6 Cycles of carboplatin/paclitaxel according to 10-step desensitisation scheduleSkin tests positive for carboplatin
2018Symptomatic platinum-sensitive disease relapseNo6 Cycles of carboplatin monotherapy according to 10-step desensitisation schedule with additional omalizumab for cycle 4–6Cycle 1: flushing, pruritus and erythema of the face and chest
Cycle 2 + 3: Anaphylaxis
Skin tests positive for carboplatin (negative for cisplatin)
Cycle 4–6: Uneventful
Skin tests persistently positive
2019Symptomatic platinum-sensitive disease relapseNo6 Cycles of carboplatin monotherapy according to 10-step desensitisation schedule with additional omalizumabNo events